China's security ministry says GSK suspected of trying to bribe officials, hospitals and doctors to boost sales and prices
Executives of British drug maker GlaxoSmithKline in China have confessed to charges of bribery and tax law violations after initial questioning by Chinese police, according to the country's security ministry.
The company is suspected of offering bribes to government officials, medical associations, hospitals and doctors to boost sales and prices, China's security ministry said in a statement on its website on Thursday.
GSK is also suspected of using fake receipts in unspecified tax law violations, the ministry added.
"After initial questioning the suspects have admitted to the crimes, and the investigation is ongoing," the statement said.
The statement did not give details on the number of executives questioned, their identities or when the questioning took place.
 |
| A pharmacist checks stocks of medicine at a hospital in Hefei, central ChinaGSK said it would co-operate with the authorities but said Thursday's announcement was the first official communication it has received about the investigation. |
"Corruption has no place in our business," said a company statement. "If evidence of such activity is provided we would of course act swiftly on it."
In recent months China has targeted foreign firms on multiple fronts including alleged price-fixing, quality controls and consumer rights, forcing companies to defend their reputations in a country where international brands often have a valuable edge over local competitors in terms of public trust.
Police in the south-central Chinese city of Changsha said last week they were investigating high-level Chinese staff at GSK on suspicion of unspecified economic crimes.
GSK said on Monday it was investigating new allegations that its staff had used improper tactics to market Botox in China, but had so far found no evidence of bribery or corruption.
GSK, Merck and other foreign and domestic drugmakers were also being investigated by China's top economic planning agency on cost and pricing issues.
China is an increasingly important market for international pharmaceutical companies, which are relying on growth in emerging markets to offset slower sales in western markets where many former blockbuster drugs have lost patent protection.
Article Source : http://www.guardian.co.uk
Azure Global’s vision is to be widely recognized as a reputed firm of financial business advisors, achieving real growth for ambitious companies and to become the first choice for F&A outsourcing for accountancy practices and businesses alike and if u want to Setup ur business in United Kingdom then its not difficult in this modern age for more info visit our site Azure Global and join us also On Facebook
No comments:
Post a Comment